Related Experiment Video
Updated: May 9, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Feasibility of implementing a comprehensive warfarin pharmacogenetics service
Edith A Nutescu1, Katarzyna Drozda, Adam P Bress
1Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL.
Pharmacotherapy
|July 19, 2013
Summary
Pharmacist-led genotype-guided warfarin dosing is procedurally feasible for hospitalized patients. Most genetic results were available for early dosing, and clinicians largely followed recommendations.
Area of Science:
- Pharmacogenomics
- Clinical Pharmacy
- Internal Medicine
Background:
- Warfarin dosing requires careful management due to its narrow therapeutic index.
- Genetic variations significantly impact warfarin metabolism and response.
- Personalized dosing strategies, including genotype-guided approaches, aim to improve warfarin therapy outcomes.
Purpose of the Study:
- To assess the procedural feasibility of a pharmacist-led interdisciplinary service for genotype-guided warfarin dosing in hospitalized patients.
- To evaluate the availability of genetic information and clinician adherence to pharmacogenetics recommendations.
Main Methods:
- Prospective observational study conducted in a 438-bed tertiary care hospital.
- Eighty patients newly starting warfarin therapy were enrolled.
- All patients received routine warfarin genotyping and clinical pharmacogenetics consultation.
Main Results:
- 76% of genotypes were available before the second warfarin dose, with a median turnaround time of 30 hours for dose recommendations.
- 44% of genotype orders were deemed appropriate.
- 73% of clinician-ordered warfarin doses were within 0.5 mg of the recommended daily dose.
Conclusions:
- A pharmacist-led pharmacogenetics service for genotype-guided warfarin dosing is procedurally feasible.
- The service demonstrated timely availability of genetic results and good adherence by medical staff.
- This model supports the integration of pharmacogenomics into routine clinical practice for warfarin management.
Related Concept Videos
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...